Evidence map›Paper›PMID 35175135›Full record

ArticleMolecular and cellular biology2022

Correction for Bjørgo et al., "Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/β-Arrestin/cAMP Phosphodiesterase 4 Complex".

Elisa Bjørgo, Silje A Solheim, Hilde Abrahamsen, George S Baillie, Kim M Brown, Torunn Berge, Klaus Okkenhaug, Miles D Houslay, Kjetil Taskén

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Elisa BjørgoBiotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslogrid.5510.1, Oslo, Norway.
Silje A SolheimBiotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslogrid.5510.1, Oslo, Norway.
Hilde AbrahamsenBiotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslogrid.5510.1, Oslo, Norway.
George S BaillieNeuroscience and Molecular Pharmacology, Wolfson Link and Davidson Buildings, Faculty of Biomedical and Life Sciences, University of Glasgowgrid.8756.c, Glasgow G12 8QQ, Scotland, United Kingdom.
Kim M BrownNeuroscience and Molecular Pharmacology, Wolfson Link and Davidson Buildings, Faculty of Biomedical and Life Sciences, University of Glasgowgrid.8756.c, Glasgow G12 8QQ, Scotland, United Kingdom.
Torunn BergeBiotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslogrid.5510.1, Oslo, Norway.
Klaus OkkenhaugLaboratory of Lymphocyte Signaling and Development, Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Miles D HouslayNeuroscience and Molecular Pharmacology, Wolfson Link and Davidson Buildings, Faculty of Biomedical and Life Sciences, University of Glasgowgrid.8756.c, Glasgow G12 8QQ, Scotland, United Kingdom.
Kjetil TaskénBiotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslogrid.5510.1, Oslo, Norway.ORCID 0000-0003-2841-4697

Funding

Medical Research Council G0600765
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35175135
PMCPMC8852739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.